Biogen
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Study of the Safety, Tolerability, Pharmacokinetics and Safety of BG00010 (Neublastin) in Subjects With Sciatica.
- Conditions
- Sciatica
- Interventions
- Drug: BG00010 (Neublastin)Drug: Placebo
- First Posted Date
- 2011-07-29
- Last Posted Date
- 2014-09-09
- Lead Sponsor
- Biogen
- Target Recruit Count
- 56
- Registration Number
- NCT01405833
- Locations
- 🇳🇱
Research Site, Leiden, Netherlands
Single Ascending Dose Study of BIIB037 in Participants With Alzheimer's Disease
- First Posted Date
- 2011-07-19
- Last Posted Date
- 2015-03-23
- Lead Sponsor
- Biogen
- Target Recruit Count
- 53
- Registration Number
- NCT01397539
- Locations
- 🇺🇸
Compass Research, LLC, Orlando, Florida, United States
🇺🇸Brain Matters Research, Delray Beach, Florida, United States
🇺🇸Insight Clinical Trials, LLC, Beachwood, Ohio, United States
STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- Conditions
- Idiopathic Pulmonary Fibrosis (IPF)
- Interventions
- Drug: Placebo
- First Posted Date
- 2011-06-10
- Last Posted Date
- 2020-02-28
- Lead Sponsor
- Biogen
- Target Recruit Count
- 41
- Registration Number
- NCT01371305
- Locations
- 🇺🇸
Research Site, Houston, Texas, United States
Avonex PEN Satisfaction and Patients Experience Clinical Trial
- Conditions
- Multiple Sclerosis
- First Posted Date
- 2011-06-03
- Last Posted Date
- 2013-09-16
- Lead Sponsor
- Biogen
- Target Recruit Count
- 89
- Registration Number
- NCT01366040
- Locations
- 🇨🇦
Foothills Medical Center, Calgary, Alberta, Canada
🇨🇦MUN Hospital, St. John's, Newfoundland and Labrador, Newfoundland and Labrador, Canada
🇨🇦Neuro Rive-Sud, Greenfield Park, Quebec, Canada
A Study To Assess Effects Of PF-04958242 On Bold Functional Magnetic Resonance Imaging During Working Memory Activation And Arterial Spin Labeling At Rest In Healthy Subjects
- First Posted Date
- 2011-06-03
- Last Posted Date
- 2019-12-24
- Lead Sponsor
- Biogen
- Target Recruit Count
- 112
- Registration Number
- NCT01365338
- Locations
- 🇺🇸
Research Site, New Haven, Connecticut, United States
Long-Term Safety and Efficacy Study of Peginterferon Beta-1a
- First Posted Date
- 2011-04-08
- Last Posted Date
- 2017-01-13
- Lead Sponsor
- Biogen
- Target Recruit Count
- 1077
- Registration Number
- NCT01332019
- Locations
- 🇬🇧
Research Site, Sheffield, United Kingdom
A Safety Study in Healthy Volunteers of the Single-Use Autoinjector Containing Placebo of BG9418 Interferon Beta-1a With a 25-Gauge × 1-Inch Needle
- Conditions
- Healthy
- Interventions
- Device: 25G x 1" Needle Autoinjector
- First Posted Date
- 2011-03-11
- Last Posted Date
- 2011-08-12
- Lead Sponsor
- Biogen
- Target Recruit Count
- 80
- Registration Number
- NCT01313364
- Locations
- 🇨🇦
Research Site, Toronto, Ontario, Canada
Alternate Dosing Regimens of BG00012 in Healthy Volunteers
- Conditions
- Healthy
- Interventions
- Drug: Dimethyl Fumarate (BG00012)Drug: BG00012 matching placebo
- First Posted Date
- 2011-01-21
- Last Posted Date
- 2023-08-23
- Lead Sponsor
- Biogen
- Target Recruit Count
- 56
- Registration Number
- NCT01281111
- Locations
- 🇺🇸
Research Site, Saint Paul, Minnesota, United States
Avonex-evaluation of Quality of Life and Convenience in Belgian Participants - The AVAIL Study
- Conditions
- Multiple Sclerosis
- First Posted Date
- 2011-01-07
- Last Posted Date
- 2015-10-20
- Lead Sponsor
- Biogen
- Target Recruit Count
- 100
- Registration Number
- NCT01272128
- Locations
- 🇧🇪
Research Site, Liège, Belgium
Safety Study of BIIB033 in Subjects With Multiple Sclerosis
- Conditions
- Multiple SclerosisRelapsing-Remitting Multiple Sclerosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2010-11-19
- Last Posted Date
- 2017-01-09
- Lead Sponsor
- Biogen
- Target Recruit Count
- 47
- Registration Number
- NCT01244139
- Locations
- 🇺🇸
Research Site, Centennial, Colorado, United States